Sanofi (ENXTPA:SAN) - Stock Price, News & Analysis

SAN Stock Overview

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.

SAN fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	5/6
Financial Health	6/6
Dividends	5/6

Rewards

Trading at 51.8% below our estimate of its fair value

Earnings are forecast to grow 9.61% per year

Earnings grew by 29.7% over the past year

Pays a reliable dividend of 3.46%

Trading at good value compared to peers and industry

Risk Analysis

No risks detected for SAN from our risk checks.

Sanofi Competitors

Ipsen

ENXTPA:IPN

€10.2b

Virbac

ENXTPA:VIRP

€2.1b

Euroapi

ENXTPA:EAPI

€1.1b

Vetoquinol

ENXTPA:VETO

€911.0m

Price History & Performance

Summary of all time highs, changes and price drops for Sanofi
Historical stock prices
Current Share Price	€102.78
52 Week High	€105.18
52 Week Low	€77.10
Beta	0.40
1 Month Change	4.12%
3 Month Change	3.99%
1 Year Change	32.71%
3 Year Change	19.26%
5 Year Change	33.60%
Change since IPO	147.07%

Recent updates

Shareholder Returns

	SAN	FR Pharmaceuticals	FR Market
7D	0.7%	0.4%	-3.3%
1Y	32.7%	30.7%	19.1%

Return vs Industry: SAN exceeded the French Pharmaceuticals industry which returned 30.7% over the past year.

Return vs Market: SAN exceeded the French Market which returned 19.1% over the past year.

Price Volatility

Is SAN's price volatile compared to industry and market?
SAN volatility
SAN Average Weekly Movement	2.5%
Pharmaceuticals Industry Average Movement	4.0%
Market Average Movement	3.8%
10% most volatile stocks in FR Market	9.3%
10% least volatile stocks in FR Market	2.0%

Stable Share Price: SAN is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: SAN's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1973	91,573	Paul Hudson	https://www.sanofi.com

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Sanofi Fundamentals Summary

How do Sanofi's earnings and revenue compare to its market cap?
SAN fundamental statistics
Market Cap	€128.85b
Earnings (TTM)	€8.62b
Revenue (TTM)	€46.05b

15.0x

P/E Ratio

2.8x

P/S Ratio

Is SAN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
SAN income statement (TTM)
Revenue	€46.05b
Cost of Revenue	€13.91b
Gross Profit	€32.14b
Other Expenses	€23.52b
Earnings	€8.62b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Oct 27, 2023

Earnings per share (EPS)	6.87
Gross Margin	69.80%
Net Profit Margin	18.71%
Debt/Equity Ratio	26.0%

How did SAN perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

52%

Payout Ratio

SAN Stock Overview

Rewards

Risk Analysis

Sanofi Competitors

ENXTPA:IPN

€10.2b

ENXTPA:VIRP

€2.1b

ENXTPA:EAPI

€1.1b

ENXTPA:VETO

€911.0m

Price History & Performance

Recent News & Updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Atnahs Pharma UK Limited acquired Global Central Nervous System Portfolio from Sanofi (ENXTPA:SAN).

Sanofi Announces Changes to Its Executive Committee

Sanofi, Annual General Meeting, Apr 30, 2024

Sanofi Announce that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Atnahs Pharma UK Limited acquired Global Central Nervous System Portfolio from Sanofi (ENXTPA:SAN).

Sanofi Announces Changes to Its Executive Committee

Sanofi, Annual General Meeting, Apr 30, 2024

Sanofi Announce that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices

Is There An Opportunity With Sanofi's (EPA:SAN) 47% Undervaluation?

Second quarter 2023 earnings: EPS misses analyst expectations

Sanofi Provides Earnings Guidance for the Year 2023

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

We Think Sanofi (EPA:SAN) Can Manage Its Debt With Ease

Sanofi Approves Distribution of A Cash Dividend, Payable on June 1, 2023

Sanofi Announces New Data from the Harmonie Phase 3B Clinical Trial Show an 83.21% Reduction in RSV Infant Hospitalizations in a Real-World Clinical Trial Setting

Upcoming dividend of €3.56 per share at 3.5% yield

Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted Pcsk9 Patent Claims in Amgen V Sanofi

First quarter 2023 earnings: EPS exceeds analyst expectations

Is Sanofi (EPA:SAN) Trading At A 35% Discount?

Does Sanofi (EPA:SAN) Have A Healthy Balance Sheet?

Sanofi Announces Executive Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

Sanofi Provides Earnings Guidance for the Year 2023

Sanofi Announces NEJM Publishes Once-Weekly Efanesoctocog Alfa Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hemophilia A

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Expands the Marketing Authorization for Dupixent® (Dupilumab) in the European Union

Sanofi Announces NEJM Publishes Data Demonstrating Clinically Meaningful Prevention of Bleeds and Superior Bleed Protection for Efanesoctocog Alfa

Sanofi Commences Dosing in a Phase 2 Study of SAR443820 (DNL788) in Individuals with Multiple Sclerosis

Is There An Opportunity With Sanofi's (EPA:SAN) 48% Undervaluation?

U.S. Food and Drug Administration Accepts Nirsevimab Application as First Protective Option Against RSV Disease for all Infants

Sanofi and Regeneron Pharmaceuticals, Inc. Announce Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Sanofi to Report Q1, 2023 Results on Apr 27, 2023

Sanofi Confirms That Any Offer for Horizon, If Made by Sanofi, Will Be Solely in Cash

Sanofi Receives Marketing Authorization for Enjaymo from the European Commission

European Commission Approves Enjaymov for Treatment of Hemolytic Anemia in Adult Patients with Cold Agglutinin Disease

Sanofi and GSK’s Next-Generation COVID-19 Booster Vaccine VidPrevtyn® Beta Approved by the European Commission

Sanofi and AstraZeneca Announce European Commission Grants First Approval Worldwide of Beyfortus (Nirsevimab) for Prevention of RSV Disease in Infants

Sanofi Upgrades Earnings Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Regeneron Pharmaceuticals, Inc. and Sanofi Present Late-Breaking Positive Results from Phase 3 Trial Evaluating the Investigational Use of Dupixent (dupilumab) in Children Aged 1 to 11 Years with Active Eosinophilic Esophagitis

Sanofi, Annual General Meeting, May 25, 2023

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Approval of Dupixent® (Dupilumab) by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

Sanofi to Report Q3, 2022 Results on Oct 28, 2022

Is Sanofi (EPA:SAN) A Risky Investment?

AstraZeneca and Sanofi Recommends Beyfortus for Marketing Authorisation in the European Union

Regeneron Pharmaceuticals, Inc. and Sanofi Present Detailed Positive Results from the Second of Two Phase 3 Trials (PRIME) Evaluating Dupixent

Sanofi Announces the Sales Guidance for Third and Fourth Quarter of 2022

Late-Breaking Dupixent® (Dupilumab) Data At Ers 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-To-Severe Asthma